Lotus Eye Hospital and Institute Management

Management Kriterienprüfungen 4/4

Lotus Eye Hospital and Institute's CEO ist Kuttapalayam Ramalingam, ernannt in Aug 2020, hat eine Amtszeit von 3.75 Jahren. besitzt direkt 1.43% der Aktien des Unternehmens, im Wert von ₹18.02M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.7 Jahre bzw. 4.4 Jahre.

Wichtige Informationen

Kuttapalayam Ramalingam

Geschäftsführender

₹1.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.2yrs
Eigentum des Geschäftsführers	1.4%
Durchschnittliche Amtszeit des Managements	4.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06

Geschäftsführer

Kuttapalayam Ramalingam (74 yo)

4.2yrs

Amtszeit

₹1,200,000

Vergütung

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kuttapalayam Ramalingam	CEO & Executive Director	4.2yrs	₹1.20m	1.43% ₹ 24.6m
Ramanujam Reghunathan	Chief Financial Officer	2.4yrs	₹1.70m	keine Daten
Mohanmenon Menon	Company Secretary & Compliance Officer	2.7yrs	₹1.08m	keine Daten
Sangeetha Sundaramoorthy	MD & Director	4.1yrs	₹3.09m	18.84% ₹ 322.8m
Rajkumar Sundaramoorthy	Vice President of Administration	6.4yrs	keine Daten	0.21% ₹ 3.5m

4.1yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrenes Management: LOTUSEYEDas Führungsteam des Unternehmens gilt als erfahren (3.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kuttapalayam Ramalingam	CEO & Executive Director	3.7yrs	₹1.20m	1.43% ₹ 24.6m
Sangeetha Sundaramoorthy	MD & Director	4.9yrs	₹3.09m	18.84% ₹ 322.8m
Rajkumar Sundaramoorthy	Vice President of Administration	4.8yrs	keine Daten	0.21% ₹ 3.5m
Kavetha Sundaramoorthy	Chairman of the Board	8.4yrs	₹150.00k	18.78% ₹ 321.8m
Sengodagounder Natesan	Independent Director	3.8yrs	₹200.00k	keine Daten
Gopalakrishnan Veeramani	Independent Non-Executive Director	1.8yrs	₹200.00k	keine Daten
Perumalsamy Mahendran	Independent Non-Executive Director	1.7yrs	₹175.00k	keine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: LOTUSEYEDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

Lotus Eye Hospital and Institute Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Aug 13, 2024

Vice President of Administration recently sold ₹173m worth of stock

Vice President of Administration recently sold ₹18m worth of stock

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

New minor risk - Share price stability

Full year 2024 earnings released: EPS: ₹1.40 (vs ₹1.96 in FY 2023)

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Aug 13, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹1.40 (vs ₹1.96 in FY 2023)

Vice President of Administration recently sold ₹173m worth of stock

Investor sentiment deteriorates as stock falls 24%

Lotus Eye Hospital and Institute Limited to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2024 earnings released: EPS: ₹0.32 (vs ₹0.56 in 3Q 2023)

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Vice President of Administration recently sold ₹18m worth of stock

Second quarter 2024 earnings released: EPS: ₹0.41 (vs ₹0.43 in 2Q 2023)

Investor sentiment improves as stock rises 18%

Upcoming dividend of ₹0.50 per share at 0.6% yield

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹0.67 (vs ₹0.66 in 1Q 2023)

Lotus Eye Hospital and Institute Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 23%

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Full year 2023 earnings released: EPS: ₹1.96 (vs ₹1.44 in FY 2022)

Lotus Eye Hospital and Institute Limited Recommends Final Dividend for the Financial Year 2022-23

Investor sentiment improves as stock rises 21%

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.67 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.60 in 2Q 2022)

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: EPS: ₹0.66 (vs ₹0.09 loss in 1Q 2022)

Investor sentiment improved over the past week

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹1.44 (vs ₹0.75 in FY 2021)

Lotus Eye Hospital and Institute Limited Announces Appointment of Ramanujam Reghunathan as Chief Financial Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Lotus Eye Hospital and Institute Limited Appoints M Achuth Menon as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹0.50 per share

First quarter 2022 earnings released: ₹0.09 loss per share (vs ₹0.32 loss in 1Q 2021)

Full year 2021 earnings released: EPS ₹0.75 (vs ₹0.51 in FY 2020)

CEO & Additional Executive Director recently bought ₹2.0m worth of stock

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

MD & Whole Time Director recently bought ₹240k worth of stock

New 90-day high: ₹39.75

Lotus Eye Hospital and Institute Limited Announces Executive Appointments

Third quarter 2021 earnings released: EPS ₹0.51 (vs ₹0.08 in 3Q 2020)

Lotus Eye Hospital and Institute Limited Announces Demise of Founder Dr. S.K. Sundaramoorthy

New 90-day high: ₹37.90

New 90-day high: ₹34.40

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer recently bought ₹2.0m worth of stock

New 90-day high: ₹32.90

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

MD & Whole Time Director recently bought ₹198k worth of stock

Second quarter 2021 earnings released: EPS ₹0.04

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Nov 28, 2020

Lotus Eye Hospital and Institute Limited to Report First Half, 2021 Results on Nov 11, 2020

Chief Executive Officer recently bought ₹229k worth of stock

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

First quarter earnings released

First quarter earnings released